CTRI/2019/04/018860已完成2 期
Three arm phase II/III Randomized Controlled Trial in patients with unresectable/metastatic Gall Bladder Cancer with poor performance status-Best supportive care/Erlotinib/Capecitabine
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •cytologically/pathologically confirmed Gall bladder cancer patients with poor performance status with adequate marrow and organ function,adjuvant chemotherapy if given should have been completed more than six months ago
排除标准
- •Active malignancy other than biliary tract cancer,impaired liver function tests despite biliary drainage,lactating and pregnant women,previous exposure to Erlotinib or Capecitabine within six months,HIV positive patients
研究者
相似试验
进行中（未招募）
1 期
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000548-25-BEPharma Mar S.A. Sociedad Unipersonal120
进行中（未招募）
不适用
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000548-25-FRPharma Mar S.A. Sociedad Unipersonal120
进行中（未招募）
1 期
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 16.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000548-25-ITPharma Mar S.A. Sociedad Unipersonal120
进行中（未招募）
1 期
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000548-25-ESPharma Mar S.A. Sociedad Unipersonal69
进行中（未招募）
3 期
To study effect of two vaccines in preventing spread of tuberculosis in persons living with new tuberculosis patients.CTRI/2019/01/017026Indian Council of Medical Research12,721